Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.72 |
| ▸ | NPC1 | O15118 | 5/20 | 0.72 |
| ▸ | RAB9A | P51151 | 5/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 9/20 | 0.68 |
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.67 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.67 |
| ▸ | RELA | Q04206 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.67 |
| ▸ | F2RL3 | Q96RI0 | 8/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23657842 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL10878341 | 0.80 | TP53 (1.00) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL13186820 | 0.78 | TP53 (0.74) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL5300838 | 0.77 | TP53 (0.62) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL7312308 | 0.72 | TP53 (0.64) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL5301366 | 0.71 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL19320615 | 0.71 | NPC1 (0.72) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL2540879 | 0.70 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL2540334 | 0.70 | APP (0.42) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL7312305 | 0.70 | TP53 (0.72) | SMN1; SMN2NPC1RAB9AKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10933049-B2 | Mobilizing agents and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2021-03-02 | — | — | US | disclosed |
| US-20180185328-A1 | MOBILIZING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-07-05 | — | — | US | disclosed |
| EP-3302710-A1 | MOBILIZING AGENTS AND USES THEREFOR | The University of Queensland (AU) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016191811-A1 | MOBILIZING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-12-08 | — | — | WO | disclosed |
| WO-2007034282-A2 | DIARYL-IMIDAZOLE COMPOUNDS CONDENSED WITH A HETEROCYCLE AS C3A RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185328-A1 | MOBILIZING AGENTS AND USES THEREFOR | C3AR1, CSF3R, C5AR1 | SMN1; SMN2 3345/4885NPC1 2609/4885RAB9A 2885/4885 |
| US-10933049-B2 | Mobilizing agents and uses therefor | C3AR1, CSF3R, C5AR1 | SMN1; SMN2 3345/4885NPC1 2609/4885RAB9A 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.